Aradigm Corporation
http://www.aradigm.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Aradigm Corporation
Parkinson’s Results Further Sweeten AbbVie’s Acquisition of Cerevel
Cerevel, which AbbVie is spending $8.7bn to acquire, unveiled topline results from the TEMPO-3 study of tavapadon, which an analyst said represents potentially a $1bn opportunity.
South Korea Sees Pharma Leadership Transition
Leadership succession is proceeding within South Korean pharmaceutical corporations such as Daiichi Sankyo Korea, Astellas Pharma Korea, Kyowa Kirin Korea as well as MSD Korea.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet
Glioblastoma Market Snapshot: Two Approvals In 2024 And A Rich Pipeline
Glioblastoma carries a grim prognosis. The biopharma industry is trying to improve patient outcomes, with 120 drugs in the pipeline and two anticipated approvals this year.
Company Information
- Industry
- Biotechnology
- Medical Devices
-
Pharmaceuticals
-
Drug Delivery
- Pulmonary
-
Drug Delivery
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice